血清CYFRA21－1的检测在实体恶性肿瘤诊断和预后判断中的价值

目的研究CYFRA21-1对来源于上皮细胞的实体恶性肿瘤诊断、分期及预后判断的临床意义。方法采用免疫放射分析法检测35例正常人、30例非肿瘤患者、53例恶性肿瘤患者的血清CYFRA21-1水平。结果正常人组及非肿瘤患者组检测阳性率明显低于恶性肿瘤组(P<0.001)。CYFRA21-1在来源于上皮细胞的实体恶性肿瘤中均有表达0～Ⅰ期者为(3.86±0.86)μG·L-1，Ⅱ～Ⅲa期者为(28.33±18.92)μg·L-1，Ⅲb～Ⅳ期者为(190.23±75.94)μg·L-1。随病情的发展，血清中CYFRA21-1含量明显增加(P<0.01)。结论血清CYFRA21-1的含量可作为对来源于上皮细胞的实体恶性肿瘤进行诊断、分期及预后判断的一项比较客观的指标。

Clinical Analysis of CYFRA21-1 in Diagnosis and Assesing Prognosis in Carcinoma Patients

Objective The purose of the study was to evaluate the significance of CYFRA21-1 in diagnosis,grading and assessing prognosis of malignant carcinoma developing from the epithelial cell. Methods The serum CYFRA21-1 levels were detected by immunoradiometric assay in 118 persons including 35 normal subjects,30 non-carcinoma cases and 53 malignant carcinoma cases. Results The positive rates of CYFRA21-1 were 0 in normal control group,6.00% in non-carcinoma group and 64.40% in malignant carcinoma group. The positive rate in malignant carcinoma group was significantly higher than that in normal control group and non-carcinoma group( P < 0.001). The expression of CYFRA21-1 was found in all cases of malignant carcinoma developing from the epithelial cell.The CYFRA21-1 levels were (3.86+0.86)μg·L-1 in 0～ Ⅰ stage,(28.33±18.92)μg·L-1 in H ～ Ⅲa stage and (190.23± 75.94)μ.g·L-1 in Ⅲb～ Ⅳ stage. It's value was increasing as the stage was developing(P<0.01).Conclusion Determination of serum CYFRA21-1 may serve as an objective index for diagnosis,grading and assessing prognosis of malignant carcinoma that takes origin from the epithelial ceils.